Please login to the form below

Not currently logged in
Email:
Password:

Merck strategy after Schering-Plough merger

Schering-Plough and Merck have created a new company, but point out that operations in many countries will remain separate for some time

Following yesterday's completion of the merger with Schering-Plough, Merck has pointed out that, though the two companies have formed a new global organisation, operations in many countries will remain separate for some time. The timing of the integration will vary from market to market.

The new Merck will operate as MSD outside the US and Canada.

Deepak Khanna has been appointed managing director of MSD in the UK. Prior to this, he was senior vice president and general manager of Merck/Schering-Plough Pharmaceuticals, managing all aspects of the joint venture in the US.

 

Deepak Khanna, managing director, MSD, UK

Deepak Khanna has been appointed managing director of MSD in the UK

Khanna explained the British set-up: "The new UK organisation has five main locations in the UK and employs approximately 2,600 people across three principal businesses; prescription, consumer and animal health. In human health, today's MSD in the UK markets over 80 medicines across disease areas covering every stage of life from childhood to old age. In consumer health, the company markets a number of products, including Clarityn. Intervet/Schering-Plough Animal Health supplies products for vets as well as companion animal and livestock owners." 

He continued: "Thanks to the talent and dedication of our scientists and employees, the company will offer an outstanding clinical development pipeline that will greatly increase our ability to deliver important new medicines to patients. We look forward to continuing to meet and exceed the needs of our customers and providing them with the high-quality products and service they have come to expect."

Merck's diversified portfolio of prescription medicines, vaccines, animal and consumer health products is complemented by a pipeline of more than 15 promising late-stage candidates spanning critical therapeutic categories.

The company now has approximately 106,000 employees and operations in more than 140 countries around the world, including emerging markets. It expects to generate more than 50 per cent of its revenue outside the US.  

4th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics